Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyDisease description

Long-term morbidity

9 evidence topics · 8 sources

Corticosteroid-associated adverse events: United States claims cohort of 200,298 participants

“This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The ten most common AEs occurring after systemic corticosteroid initiation (hypertension, lipid disorders, anxiety, obesity, fatigue, depression, diabetes, insomnia, cataracts, and gastritis) occurred in higher proportions of all corticosteroid user types versus non-users. The proportion of patients experiencing AEs generally increased with longer duration of corticosteroid use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“When assessed according to corticosteroid user type, lipid disorders were the most common AE among patients in the ≤ 31D group (33.0%), and hypertension was the most frequent in the > 31 to ≤ 60D, > 60D, and ≥ 90Dc groups (38.0%, 44.0%, and 49.4%, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The proportions of patients who reported skeletal conditions and avascular necrosis were ≥ 3 times higher in the ≥ 90Dc group versus non-users.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote